[
  {
    "ts": null,
    "headline": "Why Regeneron Pharmaceuticals Stock Topped the Market on Tuesday",
    "summary": "News of a significant earnings beat propelled Regeneron Pharmaceuticals (NASDAQ: REGN) to a nearly 5% share price gain on the second trading day of the week.  Regeneron's price zoomed well higher than the S&P 500 index's trajectory, which was a rise of 0.7% on the day.  The quarter saw Regeneron grow its revenue by 10% year over year to just under $3.79 billion.",
    "url": "https://finnhub.io/api/news?id=8e472d97031bfc843b533fc763b17ff5486d8584e2b553a96dbcfc4f9e41b3e4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1738712682,
      "headline": "Why Regeneron Pharmaceuticals Stock Topped the Market on Tuesday",
      "id": 132601932,
      "image": "https://g.foolcdn.com/editorial/images/806486/two-people-in-white-lab-coats-looking-at-a-computer-display.jpg",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "News of a significant earnings beat propelled Regeneron Pharmaceuticals (NASDAQ: REGN) to a nearly 5% share price gain on the second trading day of the week.  Regeneron's price zoomed well higher than the S&P 500 index's trajectory, which was a rise of 0.7% on the day.  The quarter saw Regeneron grow its revenue by 10% year over year to just under $3.79 billion.",
      "url": "https://finnhub.io/api/news?id=8e472d97031bfc843b533fc763b17ff5486d8584e2b553a96dbcfc4f9e41b3e4"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals Beats On Libtayo's Back, Unveils Dividend",
    "summary": "Regeneron stock jumped Tuesday after the biotech giant topped Wall Street's December-quarter calls on the back of its cancer drug Libtayo.",
    "url": "https://finnhub.io/api/news?id=867252a6d8ec518d9d0f47b11cbb835fb2bd2b858053193c6afbb56fb704eba0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1738703510,
      "headline": "Regeneron Pharmaceuticals Beats On Libtayo's Back, Unveils Dividend",
      "id": 132601933,
      "image": "https://media.zenfs.com/en/ibd.com/b727993c80cd23c03b1f42c9321ae4f1",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Regeneron stock jumped Tuesday after the biotech giant topped Wall Street's December-quarter calls on the back of its cancer drug Libtayo.",
      "url": "https://finnhub.io/api/news?id=867252a6d8ec518d9d0f47b11cbb835fb2bd2b858053193c6afbb56fb704eba0"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Beats on Q4 Earnings, Initiates Quarterly Dividend",
    "summary": "REGN reports better-than-expected Q4 results. However, lead drug Eylea sales decline in the United States due to competition. The company initiates a dividend program,",
    "url": "https://finnhub.io/api/news?id=06614d84f80b95282fef2b2f57a9fadef6a34cc5c22172d978f577f56f47c8a0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1738694880,
      "headline": "Regeneron Beats on Q4 Earnings, Initiates Quarterly Dividend",
      "id": 132601934,
      "image": "https://media.zenfs.com/en/zacks.com/9137c6f6ed305652874fd6a3a724cf37",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "REGN reports better-than-expected Q4 results. However, lead drug Eylea sales decline in the United States due to competition. The company initiates a dividend program,",
      "url": "https://finnhub.io/api/news?id=06614d84f80b95282fef2b2f57a9fadef6a34cc5c22172d978f577f56f47c8a0"
    }
  },
  {
    "ts": null,
    "headline": "MAIA’s lung cancer therapy 99% more likely to improve OS over chemo alone",
    "summary": "In the Phase II trial, THIO improved patients’ overall survival when taken in combination with Libtayo.",
    "url": "https://finnhub.io/api/news?id=7756d7fd40a9b0b30ffef8f512f373468a31e918f6ad6989b7de0777ea3b4d20",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1738693238,
      "headline": "MAIA’s lung cancer therapy 99% more likely to improve OS over chemo alone",
      "id": 132601935,
      "image": "https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2025/02/shutterstock_2235117017-4.jpg",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "In the Phase II trial, THIO improved patients’ overall survival when taken in combination with Libtayo.",
      "url": "https://finnhub.io/api/news?id=7756d7fd40a9b0b30ffef8f512f373468a31e918f6ad6989b7de0777ea3b4d20"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Pharma Q4 Earnings Crush Estimates, Initiates Dividend And Additional Stock Buyback Program",
    "summary": "On Tuesday, Regeneron Pharmaceuticals Inc (NASDAQ:REGN) reported fourth-quarter adjusted EPS of $12.07, up 2% year-over-year, beating the consensus of $11.29. The company reported sales of $3.79 billion, up 10%, beating the consensus of $3.75 billion. “Regeneron’s financial and commercial strength allows for continued investment in our industry-leading R&D pipeline, while simultaneously returning capital to our shareholders through our newly initiated dividend program and increased share repurch",
    "url": "https://finnhub.io/api/news?id=dce8d2b4e74d2aa1acbcacdfaa935b34ee87596e270681f2c4fffc5dcfcf3a17",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1738688560,
      "headline": "Regeneron Pharma Q4 Earnings Crush Estimates, Initiates Dividend And Additional Stock Buyback Program",
      "id": 132601936,
      "image": "https://media.zenfs.com/en/Benzinga/c123c38f55ed5a65179917bbee8e6942",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "On Tuesday, Regeneron Pharmaceuticals Inc (NASDAQ:REGN) reported fourth-quarter adjusted EPS of $12.07, up 2% year-over-year, beating the consensus of $11.29. The company reported sales of $3.79 billion, up 10%, beating the consensus of $3.75 billion. “Regeneron’s financial and commercial strength allows for continued investment in our industry-leading R&D pipeline, while simultaneously returning capital to our shareholders through our newly initiated dividend program and increased share repurch",
      "url": "https://finnhub.io/api/news?id=dce8d2b4e74d2aa1acbcacdfaa935b34ee87596e270681f2c4fffc5dcfcf3a17"
    }
  },
  {
    "ts": null,
    "headline": "Is Regeneron Pharmaceuticals (REGN) the Best Cancer Stock to Buy According to Hedge Funds?",
    "summary": "We recently published a list of the 10 Best Cancer Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against other best cancer stocks to buy. Overview of the Global Oncology Sector Cancer is the second leading cause of death […]",
    "url": "https://finnhub.io/api/news?id=899a7ab4741445abb6b7870776867df6cb1abaa29eaa2642db2de398c95a3aca",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1738679738,
      "headline": "Is Regeneron Pharmaceuticals (REGN) the Best Cancer Stock to Buy According to Hedge Funds?",
      "id": 132601937,
      "image": "https://s.yimg.com/ny/api/res/1.2/jMekiCT4mZ2_S7szsjNT5A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/9b67531d4ce9e2fbb21fef60675f48d3",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "We recently published a list of the 10 Best Cancer Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against other best cancer stocks to buy. Overview of the Global Oncology Sector Cancer is the second leading cause of death […]",
      "url": "https://finnhub.io/api/news?id=899a7ab4741445abb6b7870776867df6cb1abaa29eaa2642db2de398c95a3aca"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Q4 Earnings: Dividend And Dupixent Drive Solid Quarter - Eylea To Strike Back In 2025",
    "summary": "Regeneron reported Q4 2024 earnings today and declared its first-ever dividend of $0.88 per quarter. Click here to know what makes REGN stock a compelling buy.",
    "url": "https://finnhub.io/api/news?id=dc03facd2514a9da346ce602a1a92165fed09beffa9f3f7f05b05c259f300c52",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1738679713,
      "headline": "Regeneron Q4 Earnings: Dividend And Dupixent Drive Solid Quarter - Eylea To Strike Back In 2025",
      "id": 132553270,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/108129910/image_108129910.jpg?io=getty-c-w1536",
      "related": "REGN",
      "source": "SeekingAlpha",
      "summary": "Regeneron reported Q4 2024 earnings today and declared its first-ever dividend of $0.88 per quarter. Click here to know what makes REGN stock a compelling buy.",
      "url": "https://finnhub.io/api/news?id=dc03facd2514a9da346ce602a1a92165fed09beffa9f3f7f05b05c259f300c52"
    }
  },
  {
    "ts": null,
    "headline": "Compared to Estimates, Regeneron (REGN) Q4 Earnings: A Look at Key Metrics",
    "summary": "The headline numbers for Regeneron (REGN) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.",
    "url": "https://finnhub.io/api/news?id=bb7696636484683e5f34b14781deaa9b41a3a43c65089f35b5e5fe6801b8b7e0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1738679425,
      "headline": "Compared to Estimates, Regeneron (REGN) Q4 Earnings: A Look at Key Metrics",
      "id": 132601938,
      "image": "https://media.zenfs.com/en/zacks.com/ace7df31c7fcb10255abe7c990ea373a",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "The headline numbers for Regeneron (REGN) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.",
      "url": "https://finnhub.io/api/news?id=bb7696636484683e5f34b14781deaa9b41a3a43c65089f35b5e5fe6801b8b7e0"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron beats quarterly estimates on eczema drug demand; launches dividend program",
    "summary": "Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema treatment, Dupixent, and announced a dividend and stock buyback program, sending its shares up 2.2% premarket. U.S. sales of Eylea, which has been its long-standing cash cow, rose by 2% to $1.5 billion, including $305 million from the higher 8-milligram dose version. Analysts were expecting $1.77 billion in total Eylea sales, according to LSEG data.",
    "url": "https://finnhub.io/api/news?id=f6ed47cb815a5ac1f59eb0c588755ab080b3e43465e3574703bda8d40c1f0df7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1738674922,
      "headline": "Regeneron beats quarterly estimates on eczema drug demand; launches dividend program",
      "id": 132601939,
      "image": "https://media.zenfs.com/en/reuters-finance.com/1c2053605d401fe68094e051d1ee91ac",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema treatment, Dupixent, and announced a dividend and stock buyback program, sending its shares up 2.2% premarket. U.S. sales of Eylea, which has been its long-standing cash cow, rose by 2% to $1.5 billion, including $305 million from the higher 8-milligram dose version. Analysts were expecting $1.77 billion in total Eylea sales, according to LSEG data.",
      "url": "https://finnhub.io/api/news?id=f6ed47cb815a5ac1f59eb0c588755ab080b3e43465e3574703bda8d40c1f0df7"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron’s earnings boosted by more than doubling of U.S. sales of blockbuster eye drug Eylea",
    "summary": "Regeneron’s earnings boosted by more than doubling of U.S. sales of blockbuster eye drug Eylea",
    "url": "https://finnhub.io/api/news?id=23cef771086a9032d45821b34c76dff56f8fe4cf7c02a7ad4630a0986de274b3",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1738674240,
      "headline": "Regeneron’s earnings boosted by more than doubling of U.S. sales of blockbuster eye drug Eylea",
      "id": 132549619,
      "image": "",
      "related": "REGN",
      "source": "MarketWatch",
      "summary": "Regeneron’s earnings boosted by more than doubling of U.S. sales of blockbuster eye drug Eylea",
      "url": "https://finnhub.io/api/news?id=23cef771086a9032d45821b34c76dff56f8fe4cf7c02a7ad4630a0986de274b3"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron (REGN) Q4 Earnings and Revenues Beat Estimates",
    "summary": "Regeneron (REGN) delivered earnings and revenue surprises of 3.87% and 0.07%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?",
    "url": "https://finnhub.io/api/news?id=d5c0c79612dc0a6160532430f42054c070542d5130bb2dc987199b174632b1d9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1738673104,
      "headline": "Regeneron (REGN) Q4 Earnings and Revenues Beat Estimates",
      "id": 132601940,
      "image": "https://s.yimg.com/ny/api/res/1.2/gZA5XMnsr1RRZw6lGNAcdA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD05NDA-/https://media.zenfs.com/en/zacks.com/c65fb4556b91b6c9dc83e4eff25fede0",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Regeneron (REGN) delivered earnings and revenue surprises of 3.87% and 0.07%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?",
      "url": "https://finnhub.io/api/news?id=d5c0c79612dc0a6160532430f42054c070542d5130bb2dc987199b174632b1d9"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron: Q4 Earnings Snapshot",
    "summary": "On a per-share basis, the Tarrytown, New York-based company said it had profit of $8.06. Earnings, adjusted for stock option expense and non-recurring costs, were $12.07 per share. The results beat Wall Street expectations.",
    "url": "https://finnhub.io/api/news?id=a118d91426abc7cb28b85c93e8b80ce3adb9a4162634af25dc9493f0cc53f852",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1738670058,
      "headline": "Regeneron: Q4 Earnings Snapshot",
      "id": 132601941,
      "image": "https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "On a per-share basis, the Tarrytown, New York-based company said it had profit of $8.06. Earnings, adjusted for stock option expense and non-recurring costs, were $12.07 per share. The results beat Wall Street expectations.",
      "url": "https://finnhub.io/api/news?id=a118d91426abc7cb28b85c93e8b80ce3adb9a4162634af25dc9493f0cc53f852"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron’s (NASDAQ:REGN) Q4 Sales Top Estimates, Stock Soars",
    "summary": "Biotech company Regeneron (NASDAQ:REGN) reported Q4 CY2024 results topping the market’s revenue expectations, with sales up 10.3% year on year to $3.79 billion. Its non-GAAP profit of $12.07 per share was 7.8% above analysts’ consensus estimates.",
    "url": "https://finnhub.io/api/news?id=bf7693d97ad4c89402c542fc87c6622e3f998f415998510cd3bd28a4bb33d379",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1738669607,
      "headline": "Regeneron’s (NASDAQ:REGN) Q4 Sales Top Estimates, Stock Soars",
      "id": 132601942,
      "image": "https://s.yimg.com/ny/api/res/1.2/Vkx43ET44Ukm4snbdwReLA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02MDA-/https://media.zenfs.com/en/stockstory_922/863b7649ab1334021118a8518d7e40cd",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Biotech company Regeneron (NASDAQ:REGN) reported Q4 CY2024 results topping the market’s revenue expectations, with sales up 10.3% year on year to $3.79 billion. Its non-GAAP profit of $12.07 per share was 7.8% above analysts’ consensus estimates.",
      "url": "https://finnhub.io/api/news?id=bf7693d97ad4c89402c542fc87c6622e3f998f415998510cd3bd28a4bb33d379"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals, Inc. (REGN) Q4 2024 Earnings Call Transcript",
    "summary": "Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q4 2024 Earnings Conference Call February 4, 2025 8:30 AM ETCompany ParticipantsRyan Crowe - SVP, IRLeonard...",
    "url": "https://finnhub.io/api/news?id=6a5557f820ac4b02231d48795d7a81de4b4b40acac843e24d7edca3975b846a6",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1738668856,
      "headline": "Regeneron Pharmaceuticals, Inc. (REGN) Q4 2024 Earnings Call Transcript",
      "id": 132543620,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "REGN",
      "source": "SeekingAlpha",
      "summary": "Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q4 2024 Earnings Conference Call February 4, 2025 8:30 AM ETCompany ParticipantsRyan Crowe - SVP, IRLeonard...",
      "url": "https://finnhub.io/api/news?id=6a5557f820ac4b02231d48795d7a81de4b4b40acac843e24d7edca3975b846a6"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Reports Fourth Quarter and Full Year 2024 Financial and Operating Results; Initiates Quarterly Dividend and Increases Total Share Repurchase Capacity to ~$4.5 Billion",
    "summary": "Fourth quarter 2024 revenues increased 10% to $3.79 billion versus fourth quarter 2023Full year 2024 revenues increased 8% to $14.20 billion versus 2023; excluding RonapreveTM(a)(b), revenues increased 10%Fourth quarter 2024 Dupixent® global net sales (recorded by Sanofi) increased 15% to $3.70 billion versus fourth quarter 2023; full year 2024 Dupixent global net sales increased 22% to $14.15 billion versus 2023Fourth quarter 2024 U.S. net sales for EYLEA HD® and EYLEA® increased 2% versus four",
    "url": "https://finnhub.io/api/news?id=b93591b8aefe33115b051e40ac7a2ae6e4063bfa66ed6ac80fc0b622ebc07c89",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1738668600,
      "headline": "Regeneron Reports Fourth Quarter and Full Year 2024 Financial and Operating Results; Initiates Quarterly Dividend and Increases Total Share Repurchase Capacity to ~$4.5 Billion",
      "id": 132601943,
      "image": "https://media.zenfs.com/en/globenewswire.com/2788fcd6c9b4dcf523fc2cc341eb4142",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Fourth quarter 2024 revenues increased 10% to $3.79 billion versus fourth quarter 2023Full year 2024 revenues increased 8% to $14.20 billion versus 2023; excluding RonapreveTM(a)(b), revenues increased 10%Fourth quarter 2024 Dupixent® global net sales (recorded by Sanofi) increased 15% to $3.70 billion versus fourth quarter 2023; full year 2024 Dupixent global net sales increased 22% to $14.15 billion versus 2023Fourth quarter 2024 U.S. net sales for EYLEA HD® and EYLEA® increased 2% versus four",
      "url": "https://finnhub.io/api/news?id=b93591b8aefe33115b051e40ac7a2ae6e4063bfa66ed6ac80fc0b622ebc07c89"
    }
  },
  {
    "ts": null,
    "headline": "REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm",
    "summary": "LOS ANGELES, Feb. 4, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Regeneron Pharmaceuticals, Inc. ...",
    "url": "https://finnhub.io/api/news?id=425f2269937b507db3e37c1fde9ca5d37a02854636b7703b585c9b0e225a9596",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1738656725,
      "headline": "REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm",
      "id": 132542847,
      "image": "",
      "related": "REGN",
      "source": "Finnhub",
      "summary": "LOS ANGELES, Feb. 4, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Regeneron Pharmaceuticals, Inc. ...",
      "url": "https://finnhub.io/api/news?id=425f2269937b507db3e37c1fde9ca5d37a02854636b7703b585c9b0e225a9596"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron 4Q Revenue Up on Strong Sales of EYLEA HD",
    "summary": "By Rob Curran Regeneron Pharmaceuticals logged a sharp increase in fourth-quarter revenue amid strong demand for a new formulation of its EYLEA product. The biotechnology company posted...",
    "url": "https://finnhub.io/api/news?id=60562d139acdf121531d6795a414a54a3fd68cc1dfbc1d210ed5229c9d0e2262",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1738653264,
      "headline": "Regeneron 4Q Revenue Up on Strong Sales of EYLEA HD",
      "id": 132542441,
      "image": "",
      "related": "REGN",
      "source": "Finnhub",
      "summary": "By Rob Curran Regeneron Pharmaceuticals logged a sharp increase in fourth-quarter revenue amid strong demand for a new formulation of its EYLEA product. The biotechnology company posted...",
      "url": "https://finnhub.io/api/news?id=60562d139acdf121531d6795a414a54a3fd68cc1dfbc1d210ed5229c9d0e2262"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Launches Dividend Program, Boost Stock Buybacks",
    "summary": "By Colin Kellaher Regeneron Pharmaceuticals is stepping up its shareholder returns with the launch of a quarterly dividend and a $3 billion increase to its stock-buyback program. Regeneron on...",
    "url": "https://finnhub.io/api/news?id=3a2cb5014ca59437487950eb4fcb0cf26778b41748ed3467a82433604ff19bf5",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1738653074,
      "headline": "Regeneron Launches Dividend Program, Boost Stock Buybacks",
      "id": 132542436,
      "image": "",
      "related": "REGN",
      "source": "Finnhub",
      "summary": "By Colin Kellaher Regeneron Pharmaceuticals is stepping up its shareholder returns with the launch of a quarterly dividend and a $3 billion increase to its stock-buyback program. Regeneron on...",
      "url": "https://finnhub.io/api/news?id=3a2cb5014ca59437487950eb4fcb0cf26778b41748ed3467a82433604ff19bf5"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron 4Q Rev Up on Strong Sales of EYLEA HD",
    "summary": "Regeneron 4Q Rev Up on Strong Sales of EYLEA HD",
    "url": "https://finnhub.io/api/news?id=3f706cdadc55b24a19eefea1440aafb515f237173fce78ce18b728c02e6317cf",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1738652280,
      "headline": "Regeneron 4Q Rev Up on Strong Sales of EYLEA HD",
      "id": 132549620,
      "image": "",
      "related": "REGN",
      "source": "MarketWatch",
      "summary": "Regeneron 4Q Rev Up on Strong Sales of EYLEA HD",
      "url": "https://finnhub.io/api/news?id=3f706cdadc55b24a19eefea1440aafb515f237173fce78ce18b728c02e6317cf"
    }
  },
  {
    "ts": null,
    "headline": "Alphabet results lead busy day of earnings",
    "summary": "Alphabet results lead busy day of earnings",
    "url": "https://finnhub.io/api/news?id=e5dfd889369f51d42634e6a306820faabbe83decbd89331f4eace874326224f3",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1738648510,
      "headline": "Alphabet results lead busy day of earnings",
      "id": 132543886,
      "image": "",
      "related": "REGN",
      "source": "MarketWatch",
      "summary": "Alphabet results lead busy day of earnings",
      "url": "https://finnhub.io/api/news?id=e5dfd889369f51d42634e6a306820faabbe83decbd89331f4eace874326224f3"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - REGN",
    "summary": "NEW YORK, Feb. 4, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Regeneron Pharmaceuticals, Inc. of a class action securities lawsuit. ...",
    "url": "https://finnhub.io/api/news?id=61444561d916bed187a7fdb0514f7a08ced60d64b91e698b36f58614803b1cf1",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1738647981,
      "headline": "Regeneron Pharmaceuticals, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - REGN",
      "id": 132541886,
      "image": "",
      "related": "REGN",
      "source": "Finnhub",
      "summary": "NEW YORK, Feb. 4, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Regeneron Pharmaceuticals, Inc. of a class action securities lawsuit. ...",
      "url": "https://finnhub.io/api/news?id=61444561d916bed187a7fdb0514f7a08ced60d64b91e698b36f58614803b1cf1"
    }
  }
]